Form 4: Rhythm Pharma CTO Exercises Options, Sells Shares

Rhythm Pharmaceuticals' Chief Technical Officer, Joseph Shulman, executed a pre-planned transaction, exercising stock options and selling an equivalent number of common shares.

Summary

• Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals, Inc. (RYTM), engaged in a series of transactions on September 2, 2025.
• Shulman exercised stock options to acquire 2,094 shares of common stock at an exercise price of $27.35 per share.
• Additionally, Shulman exercised stock options to acquire 14,687 shares of common stock at an exercise price of $30.66 per share.
• Immediately following the option exercises, Shulman sold 16,781 shares of common stock at a weighted average price of $105.298 per share, with individual sales ranging from $105.00 to $105.82.
• The sale was conducted pursuant to a Rule 10b5-1 instruction adopted on August 8, 2024.
• Following these transactions, Shulman directly beneficially owns 8,509 shares of common stock.
• Shulman also directly beneficially owns 16,750 stock options with an exercise price of $27.35 and 22,813 stock options with an exercise price of $30.66.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be a concern, this transaction represents a profitable exercise of options and a pre-planned sale under a 10b5-1 plan, which is a routine event for executive compensation and personal financial management. It does not suggest any negative outlook on the company's fundamentals.

Positives

• The Chief Technical Officer realized a significant profit from exercising options and selling shares, with the sale price of $105.298 being substantially higher than the exercise prices of $27.35 and $30.66.
• The transaction was executed under a pre-arranged Rule 10b5-1 plan, indicating a structured approach to personal financial management rather than a reaction to new, undisclosed information.

Negatives

• Insider selling, even if pre-planned, can sometimes be viewed with caution by investors, though the context of option exercise often mitigates this concern.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sale reported was effected pursuant to a Rule 10b5-1 instruction adopted on August 8, 2024.

Industry Context

This insider transaction is a routine disclosure for publicly traded companies and does not inherently reflect broader industry trends or competitive dynamics. It primarily pertains to an individual executive's compensation and personal financial planning.

Corporate Governance

Stakeholder Impact

• Shareholders: May observe the Chief Technical Officer's profitable transaction, which could be viewed as a positive for executive compensation, but the sale itself is a neutral event given the 10b5-1 plan.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned insider transaction (exercise of options and subsequent sale of shares) by the Chief Technical Officer. While the sale price indicates a significant profit for the insider, the transaction itself does not provide new fundamental information about the company's operational performance or future prospects to warrant a change in investment recommendation. The sale was executed under a Rule 10b5-1 plan, suggesting it was for personal financial planning rather than a reaction to new, undisclosed information.

Keywords

Rhythm Pharmaceuticals, RYTM, Joseph Shulman, Form 4, Insider Trading, Stock Options, Share Sale, CTO, 10b5-1 Plan, Executive Compensation